ES2528951T3 - Secuencias consenso, antígenos y transgenes del VIH-1 del clado A - Google Patents

Secuencias consenso, antígenos y transgenes del VIH-1 del clado A Download PDF

Info

Publication number
ES2528951T3
ES2528951T3 ES11005764.3T ES11005764T ES2528951T3 ES 2528951 T3 ES2528951 T3 ES 2528951T3 ES 11005764 T ES11005764 T ES 11005764T ES 2528951 T3 ES2528951 T3 ES 2528951T3
Authority
ES
Spain
Prior art keywords
clade
hiv
transgenes
antigens
consensus sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11005764.3T
Other languages
English (en)
Inventor
Kalpana Gupta
Nicholas Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International AIDS Vaccine Initiative Inc
Original Assignee
International AIDS Vaccine Initiative Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International AIDS Vaccine Initiative Inc filed Critical International AIDS Vaccine Initiative Inc
Application granted granted Critical
Publication of ES2528951T3 publication Critical patent/ES2528951T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Una composición inmunogénica o de vacuna que comprende un polinucleótido que codifica un antígeno Env del VIH-1 del Clado A, en el que el antígeno Env tiene la secuencia de aminoácidos ilustrada en la Fig. 17 y está codificada por la secuencia de nucleótidos ilustrada en la Fig. 17.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
E11005764
27-01-2015
A_TZA341_1
6,05523 TZ 2001
A_MSA4072_
0,05583 KE 2000
A_MSA4076_
0,056 KE 2000
A_KNH1199
0,05687 KE 2000
A_MSA407_
0,05947 KE 2000
A_98UG5713
0,06038 UG 1998
A_KEQ23-17
0,06072 KE 1994
A_KNH1209_
0,06101 KE 2000
A_NKU3005_
0,06108 KE 2000
A_SE7253SO
0,06113 SO 1994
A_98UG5713
0,06119 UG 1998
A_SE8538_
0,06137 TZ 1995
A_KNH1088_
0,06262 KE 1999
A_KER2608_
0,065 KE 2000
A_99UGA070
0,06531 UG 1999
A_KER2012
0,06654 KE 2000
A_KER2009_
0,0674 KE 2000
A_99UGG033
0,06871 UG 1999
A_KSM4030
0,07026 KE 2000
A_KSM4021
0,07145 KE 1999
A_98UG5713
0,07189 UG 1998
A_SE8891UG
0,07197 UG 1995
A_SE8131UG
0,07462 UG 1995
A_97TZ03_1
0,07653 TZ 1997
A_KNH1135_
0,07687 KE 1999
A_98UG5714
0,0781 UG 1998
A_UGU455_1
0,08349 UG 1985
A_MSA4069_
0,08867 KE 2000
Se analizaron las secuencias de aminoácidos de las proteínas Gag de 39 cepas no recombinantes del VIH del clado A. La tabla 1 enumera las 39 cepas usadas y se refiere a cada una por su número de registro de Genbank. La tabla 1 también identifica el país y el año del aislamiento de cada una de estas 39 cepas. 20 de las cepas eran de Kenia, 12 de Uganda, 6 de Tanzania y 1 de Somalia. 20 de las cepas se aislaron entre 2000 y 2002, 10 se aislaron entre 1997 y 1999, 6 se aislaron entre 1994 y 1996 y 3 se aislaron antes de 1993.
Las secuencias de la proteína Gag se alinearon agregando espacios para preservar el alineamiento en regiones con inserciones o deleciones. Se derivó una secuencia consenso del 50%. La secuencia consenso de aminoácidos
16
imagen15
E11005764
27-01-2015
A_MSA4076_
6,02564 KE 2000
A_KNH1207_
6,0265 KE 2000
A_NKU3005_
0,02661 KE 2000
A_TZA173_3
0,02756 TZ 2001
A_MSA4079_
0,02762 KE 2000
A_KER2009_
0,02765 KE 2000
A_TZA195_3
0,02881 TZ 2001
A_KSM4021
0,02881 KE 1999
A_SE7535UG
0,02883 UG 1994
A_MSA4069_
0,02886 KE 2000
A_SE6594UG
0,02889 UG 1993
A_98UG5713
0,02975 UG 1998
A_KNH1135_
0,0299 KE 1999
A_92UG037_
0,02993 UG 1992
A_KNH1209_
0,03202 KE 2000
A_99UGG033
0,03291 UG 1999
A_KER2008_
0,03294 KE 2000
A_KSM4030
0,0343 KE 2000
A_KNH1199_
0,03439 KE 2000
A_99UGA070
6,03537 UG 1999
A MSA4072
0,03625 KE 2000
A_KNH1144_
0,03863 KE 2000
A_98UG5713
0,04178 UG 1998
A_UGU455_3
0,04294 UG 1985
A_98UG5713
0,04808 UG 1998
La figura 4 ilustra en forma gráfica la distancia de la secuencia de aminoácidos de cada cepa con respecto a la secuencia consenso de aminoácidos e identifica las tres cepas que tienen las secuencias más similares a las secuencias consenso. Esas tres cepas son la cepa MSA4070 de un donante de sangre anónimo en Kenia meridional en el año 2000, la cepa SE7235SO que se obtuvo en 1994 de un individuo en Suecia que se pensaba que había sido infectado en Somalia, y la cepa SE8538 que se obtuvo en 1995 de un individuo en Suecia que se pensaba que había sido infectado en Tanzania.
Ejemplo 3: Secuencia consenso para Env del VIH del clado A
Tabla 3
Distancia con respecto al consenso
País Año
18
E11005764
27-01-2015
A,cons
0
A_KEQ23-17
0,06307 KE 1994
A_TZA341_1
0,06413 TZ 2001
A_KNH1088_
0,06524 KE 1999
A_KNH1209_
0,0699 KE 2000
A_KHNH1144_
0,07088 KE 2000
A_99UGA070
0,07365 UG 1999
A_MSA4072_
0,07516 KE 2000
A_KSM4021
0,0778 KE 1999
A_97TZ021_1
0,07825 TZ 1997
A_KNH1199_
0,07883 KE 2000
A_MSA4079_
0,07944 KE 2000
A_SE7535UG
0,08375 UG 1994
A_SE8538TZ
0,08432 TZ 1995
A_98UG5713
0,08462 UG 1998
A_97TZ03_1
0,08541 TZ 1997
A_MSA4070_
0,0874 KE 2000
A_NKU3005_
0,0884 KE 2000
A_TZA173_12
0,09046 TZ 2001
A_KNH1207_
0,09106 KE 2000
A_TZA195_1
0,09389 TZ 2001
A_MSA4076_
0,09517 KE 2000
A_92UG037_
0,098 UG 1992
A_98UG5714
0,09816 UG 1998
A_SE7253SO
0,09886 SO 1994
A_KER2012
0,09984 KE 2000
A_98UG5713
0,10139 UG 1998
A_SE6594UG
0,10195 UG 1993
A_SE8891UG
0,10225 UG 1995
A_UGU455_1
0,10314 UG 1985
A_KER2009_
0,10338 KE 2000
A_KNH1211_
0,11319 KE 2000
A_SE8131UG
0,11321 UG 1995
19
imagen16
E11005764
27-01-2015
A NKU3005
0,0709
A SE7535UG
0,07117
A 98UG5714
0,07613
A SE6594UG
0,07634
A TZA341 1
0,0805
A MSA4069
0,08097
A KNH1199
0,08213
A 97TZ02 1
0,08276
A KSM4030
0,08704
A KSM4021
0,08795
A MSA4076
0,08873
A KNH1209
0,0899
A KER2012
0,09224
A KNH1144
0,09577
A KER2008
0,09703
A MSA4072
0,09892
A 98UG5713
0,09892
A 99UGG033
0,09967
A KNH1088
0,10303
A 92UG037
0,10654
A SE8538TZ
0,10996
A KER2009
0,1102
A MSA4079
0,11083
A KSM4024
0,11126
A SE8131UG
0,11326
A SE7253SO
0,11453
A KNH1207
0,11549
A TZA173 1
0,13766
21
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22

Claims (1)

  1. imagen1
ES11005764.3T 2006-06-02 2007-06-04 Secuencias consenso, antígenos y transgenes del VIH-1 del clado A Active ES2528951T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81081606P 2006-06-02 2006-06-02
US810816P 2006-06-02

Publications (1)

Publication Number Publication Date
ES2528951T3 true ES2528951T3 (es) 2015-02-13

Family

ID=38802278

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11005764.3T Active ES2528951T3 (es) 2006-06-02 2007-06-04 Secuencias consenso, antígenos y transgenes del VIH-1 del clado A
ES07798067T Active ES2396915T3 (es) 2006-06-02 2007-06-04 Secuencias consenso, antígenos y transgenes del VIH-1 del clado A

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07798067T Active ES2396915T3 (es) 2006-06-02 2007-06-04 Secuencias consenso, antígenos y transgenes del VIH-1 del clado A

Country Status (8)

Country Link
US (2) US8119144B2 (es)
EP (2) EP2029168B1 (es)
JP (1) JP2009539353A (es)
AU (1) AU2007256717B2 (es)
CA (1) CA2654324A1 (es)
DK (2) DK2399602T3 (es)
ES (2) ES2528951T3 (es)
WO (1) WO2007143606A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
KR20220061285A (ko) * 2013-11-14 2022-05-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 HIV-1 EnV DNA 백신과 단백질 부스터
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
PT799058E (pt) 1994-12-24 2003-11-28 Univ Cambridge Tech Melhoramentos na funcao endometrica ou com ela relacionados
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US20020136722A1 (en) 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE60043856D1 (de) * 1999-12-23 2010-04-01 Medical Res Council Verbesserungen in oder in bezug auf immunantworten gegen hiv
AU2001268452B2 (en) 2000-06-15 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses
IT1318103B1 (it) 2000-07-03 2003-07-23 Nuovo Pignone Spa Sistema di connessione tra un ugello di bassa pressione ed untransition duct in una turbina a gas
KR20120086379A (ko) * 2003-09-17 2012-08-02 듀크 유니버시티 컨센서스／원형 면역원
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGEN, AND USES OF RENTA

Also Published As

Publication number Publication date
US8735542B2 (en) 2014-05-27
US20120219577A1 (en) 2012-08-30
US20080089909A1 (en) 2008-04-17
AU2007256717A1 (en) 2007-12-13
WO2007143606A2 (en) 2007-12-13
CA2654324A1 (en) 2007-12-13
EP2029168A2 (en) 2009-03-04
DK2029168T3 (da) 2013-01-14
US8119144B2 (en) 2012-02-21
WO2007143606A3 (en) 2008-11-13
WO2007143606A9 (en) 2008-02-14
ES2396915T3 (es) 2013-03-01
EP2029168A4 (en) 2010-10-27
JP2009539353A (ja) 2009-11-19
EP2399602A1 (en) 2011-12-28
EP2029168B1 (en) 2012-10-03
AU2007256717B2 (en) 2013-06-20
EP2399602B1 (en) 2014-11-26
DK2399602T3 (en) 2015-02-23

Similar Documents

Publication Publication Date Title
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
ES2488941T3 (es) Vectores y constructos de liberación de antígenos de virus de la gripe
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP2014534202A5 (es)
BR112022024248A2 (pt) Vacinas de combinação à base de ácido nucleico
BR112022026733A2 (pt) Imunógenos estabilizados de proteína spike (s) de coronavírus e vacinas relacionadas
SI2280721T1 (en) IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2012501959A5 (es)
AR065523A1 (es) Procedimiento para fomentar una respuesta inmunitaria frente a un patogeno y composiciones
EP3058954A3 (en) Immunogenic compositions and methods
BRPI0707300A8 (pt) Vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
AR038595A1 (es) Cepas de metaneumovirus y su uso en formulaciones de vacunas y como vectores para la expresion de secuencias antigenicas
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
ES2528951T3 (es) Secuencias consenso, antígenos y transgenes del VIH-1 del clado A
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
EA200401504A1 (ru) Слитый белок из числа регуляторных/вспомогательных белков вич
JP2013545448A5 (es)
RU2018130683A (ru) Аттенуированный вирус инфекционного бронхита
WO2006138745A3 (en) Therapeutic peptides and vaccines
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
RU2016148309A (ru) Хорошо переносимая и высокоспецифическая адаптированная рекомбиназа для рекомбинирования асимметричных участков-мишеней во множестве штаммов ретровирусов
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)